Ensysce Biosciences, Inc. files an 8-K/A disclosing an auditor's report for its acquired subsidiary, Cy Biopharma, Inc., which includes a "substantial doubt" going concern warning.
SEC EDGAR, 2026-10-16: 8-K (Item 9.01) — "substantial doubt"
Ensysce Biosciences, Inc. files an 8-K/A disclosing an auditor's report for its acquired subsidiary, Cy Biopharma, Inc., which includes a "substantial doubt" going concern warning.
Company: Ensysce Biosciences, Inc. (ENSC) Filed: 2026-10-16, 8-K (Item 9.01) Phrase: "substantial doubt" — "Our report includes an explanatory paragraph about the existence of substantial doubt concerning Cy Biopharma, Inc.’s ability to continue as a going concern." What the filing says: Ensysce Biosciences, Inc. filed an 8-K/A that includes the consent of its independent registered public accounting firm, EisnerAmper LLP. This consent refers to their report dated May 13, 2026, on the financial statements of Cy Biopharma, Inc. as of December 31, 2025 and 2024. The report contains an explanatory paragraph about the existence of substantial doubt regarding Cy Biopharma, Inc.’s ability to continue as a going concern. Ensysce Biosciences, Inc. completed the acquisition of Cy Biopharma, Inc. on August 5, 2026. Two ways it goes: A. Cy Biopharma, Inc. secures additional funding or achieves financial stability to resolve the going concern uncertainty. B. Cy Biopharma, Inc. is unable to improve its financial position, leading to further financial challenges or potential restructuring. Next date: none named Watch: A future filing by Ensysce Biosciences, Inc. detailing Cy Biopharma, Inc.'s financial performance or a new auditor's report.